

NLM Citation: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Pyrantel. [Updated 2021 May 17]. **Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/



Pyrantel

Revised: May 17, 2021.

CASRN: 22204-24-6

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the use of pyrantel pamoate during breastfeeding. It is poorly absorbed orally, so excretion into breastmilk and absorption by the breastfed infant is unlikely.[1]

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Albendazole, Mebendazole

References

1. Porto I. Antiparasitic drugs and lactation: Focus on anthelmintics, scabicides, and pediculicides. J Hum Lact. 2003;19:421–5. PubMed PMID: 14620457.

Substance Identification

Substance Name

Pyrantel

CAS Registry Number

22204-24-6

Drug Class

Breast Feeding

Lactation

Antinematodal Agents

Antiparasitic Agents